CryoPort (NASDAQ:CYRX) Issues Quarterly Earnings Results

CryoPort (NASDAQ:CYRX) released its quarterly earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07), Zacks reports. The firm had revenue of $50.22 million for the quarter, compared to analyst estimates of $48.66 million. CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%.

Here are the key takeaways from CryoPort’s conference call:

• Cryoport reported third-quarter revenue of $50.2 million, up 14% year over year, and raised its 2026 continuing-operations revenue outlook to $197 million–$199 million. Management characterized the outlook as prudent, with fourth-quarter growth expected to continue but potential upside.
• Life Sciences Services revenue rose 18%, including 20% growth in commercial cell and gene therapy activity; the company supports 23 commercial therapies and reported a record pipeline of 788 clinical trials, including 99 in Phase III. Management sees the pipeline and rising therapy adoption as drivers of future commercial growth.
• The company posted a second consecutive quarter of positive adjusted EBITDA, at $1.1 million and $1.8 million better year over year. Management expects further operating leverage as new BioServices capabilities come online, while noting that long-term margin targets remain goals rather than current results.
• Life science products revenue increased 8%, supported by animal-health demand and the Fusion freezer line, although management described animal health as cyclical and said China was stable but not a significant growth market. Four expected 2026 therapy application filings have shifted to 2027, while two potential fourth-quarter approvals have FDA decision dates.

CryoPort Price Performance

Shares of CYRX traded up $3.05 during mid-day trading on Friday, reaching $19.10. The company had a trading volume of 2,585,565 shares, compared to its average volume of 854,852. CryoPort has a twelve month low of $7.61 and a twelve month high of $19.53. The company’s 50-day moving average is $16.98 and its 200-day moving average is $13.46. The company has a market capitalization of $967.42 million, a P/E ratio of -19.69 and a beta of 1.89.

Insider Transactions at CryoPort

In other CryoPort news, CEO Jerrell Shelton sold 28,800 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total transaction of $429,408.00. Following the sale, the chief executive officer owned 1,201,814 shares of the company’s stock, valued at $17,919,046.74. This represents a 2.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is currently owned by company insiders.

Key CryoPort News

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $50.2 million, topping estimates of $48.66 million. Commercial cell and gene therapy revenue grew 20%; Cryoport supported a record 788 global clinical trials and 23 commercially approved therapies. Cryoport Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to $197 million–$199 million, a key catalyst behind the favorable reaction to results. CryoPort Shares Rise After Q3 Revenue Beat, 2026 Guidance Raise
• Positive Sentiment: Analyst actions added support: Needham raised its price target to $28 from $19 and reiterated Buy, while KeyCorp lifted its target to $20 from $17 and maintained an Overweight rating. Needham Adjusts Price Target KeyCorp Rating
• Negative Sentiment: Adjusted earnings were a loss of $0.25 per share, missing consensus estimates of a $0.18–$0.19 loss and widening from a $0.18 loss a year earlier. The earnings shortfall may temper optimism around the revenue growth and raised outlook. CryoPort Reports Q3 Loss, Tops Revenue Estimates

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Roth Capital reissued a “buy” rating and issued a $21.00 price objective on shares of CryoPort in a research report on Friday, August 7th. BTIG Research lifted their price target on CryoPort from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Needham & Company LLC upped their price target on shares of CryoPort from $19.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday. KeyCorp lifted their price target on shares of CryoPort from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Robert W. Baird set a $26.00 price objective on shares of CryoPort in a research report on Tuesday, October 13th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.69.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.